OptiBiotix Health plc
("OptiBiotix" or the "Company")
License agreement with Tata Chemicals
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached an agreement with Tata Chemicals Limited ("Tata Chemicals") to incorporate its proprietary Fossence® into SlimBiome® and LeanBiome® for the Indian market.
The agreement incorporates Tata's Fossence®, a proprietary short chain fructo-oligosaccharide ("FOS") into OptiBiotix's SlimBiome® and LeanBiome® products for the Indian market. Fossence® will be a direct replacement for the FOS used in SlimBiome® in other markets and brings scientific substantiation of health benefits shown by FOS in the Indian market (see Explore - Brochures, Whitepapers, Concept Notes & More | Tata NQ). Tata Chemicals have approved the use of the Fossence® logo on products containing SlimBiome® in India bringing a branded ingredient from a well-known and trusted source to the attention of Indian consumers.
Tata Chemicals is a global science company active in industrial chemicals, food and nutrition (Tata NQ), and agriculture listed on the Indian stock Exchange. It is part of the Tata Group which employs over one million people with annual revenues in 2022 of $300billion.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to report this agreement with Tata Chemicals which creates the opportunity to bring products containing Tatas proprietary Fossence® in SlimBiome® and LeanBiome® to the Indian market. Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands. Fossence's® established health benefits with Indian consumers and its trusted brand combined with SlimBiome's® strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women."
For further information, please contact:
| OptiBiotix Health plc | ||
| Neil Davidson, Chairman | Contact via Walbrook below | |
| Stephen O'Hara, Chief Executive | | |
|
| | |
| Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti
| | |
| Peterhouse Capital Limited (Broker) | Tel: 020 7220 9797 | |
| Duncan Vasey / Lucy Williams | | |
| | | |
| Walbrook PR Ltd | Mob: 07876 741 001 | |
| Anna Dunphy | | |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
